Dotamtate Pb-212

Sanofi, RadioMedix, and Orano Med collaborate on AlphaMedix™, a lead-212 radioligand therapy for neuroendocrine tumors, granted Breakthrough Therapy Designation by the FDA.

Sanofi, RadioMedix, and Orano Med collaborate on AlphaMedix™, a targeted alpha therapy for neuroendocrine tumors, with FDA Breakthrough Therapy Designation. Sanofi to commercialize globally, Orano Med to manufacture, and both to receive €100 million upfront plus milestones and royalties.

Sanofi, RadioMedix, and Orano Med collaborate on AlphaMedix™, a next-gen radioligand therapy for rare cancers, specifically targeting neuroendocrine tumors. The FDA granted AlphaMedix™ Breakthrough Therapy Designation based on promising clinical results, and the agreement includes upfront and milestone payments.